
|Videos|September 19, 2022
Dr. Shore on next steps with PARP inhibitors in prostate cancer
Author(s)Urology Times staff
“There’s a tremendous amount of work going on right now with PARP inhibitors in the resistant stage, but now also we’re looking at them in the sensitive stage,” says Neal D. Shore, MD.
Advertisement
Neal D. Shore, MD, discusses what’s on the horizon with PARP inhibitors in the treatment paradigm for patients with prostate cancer. Shore is medical director for the Carolina Urologic Research Center and chief medical officer, Surgical Oncology and Urology, for Genesis Care (US).
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
GPS-ProtecT study launched to validate Genomic Prostate Score in active surveillance
2
Taylor Goodstein, MD, highlights contemporary experience with gene therapies for NMIBC
3
Jim Hu, MD, discusses new posterior approach to nerve-sparing prostatectomy
4
Permanent J code for mitomycin for intravesical solution now in effect
5



















